Get the Stockscreener App
583.07
1.19%
8.0112
Regeneron Pharmaceuticals Inc stock is traded at $583.07, with a volume of 33,303.
It is up +1.19% in the last 24 hours and up +0.26% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$575.06
Open:
$576.31
24h Volume:
33,303
Relative Volume:
0.03
Market Cap:
$60.78B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.69
EPS:
39.68
Net Cash Flow:
$3.56B
1W Performance:
+4.69%
1M Performance:
+0.26%
6M Performance:
-14.22%
1Y Performance:
-49.25%
1-Day Range:
$576.31
$583.45
1-Week Range:
$555.81
$582.99
52-Week Range:
$476.49
$1,165.85
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
583.45 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.47 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.07 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
755.00 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
331.63 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron's rare bone disorder drug succeeds in late-stage trial - Reuters
Regeneron drug reduces errant bone growth in ultra-rare skeletal condition - statnews.com
Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint - MarketScreener
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial - TipRanks
Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study - MarketScreener
Regeneron posts trial win for connective disorder therapy - Seeking Alpha
Regeneron's bone disorder treatment succeeds in late-stage trial - MarketScreener
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation - The Manila Times
Regeneron's genetic disorder treatment meets main goal of late-stage trial - MarketScreener
99% Bone Formation Prevention: Regeneron's Breakthrough Drug Shows Promise for Ultra-Rare FOP Disease - Stock Titan
Woodstock Corp Has $4.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,105 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by AG2R LA Mondiale Gestion D Actifs - MarketBeat
913 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Integrity Alliance LLC. - MarketBeat
Focus Partners Wealth Sells 3,238 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aug Momentum: Is Regeneron Pharmaceuticals Inc trading at a discountJuly 2025 News Drivers & Community Consensus Stock Picks - خودرو بانک
Aug Drivers: Will Regeneron Pharmaceuticals Inc. stock recover after earningsJuly 2025 Sector Moves & Precise Trade Entry Recommendations - خودرو بانک
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - MarketScreener
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - Benzinga
Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial - Yahoo Finance
Portfolio Recap: What is Regeneron Pharmaceuticals Inc. s 5 year growth outlookJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
RMR Wealth Builders Acquires 593 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
GuoLine Advisory Pte Ltd Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Harbor Investment Advisory LLC Sells 523 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Central Pacific Bank Trust Division Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Acadian Asset Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Voleon Capital Management LP - MarketBeat
MBB Public Markets I LLC Buys Shares of 476 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Surprises Report: Can Regeneron Pharmaceuticals Inc. reach all time highs this year - خودرو بانک
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight - Yahoo Finance
Custom watchlist performance reports with Regeneron Pharmaceuticals Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
DOJ Probe and Eylea Sales Pressures Could Be a Game Changer for Regeneron Pharmaceuticals (REGN) - simplywall.st
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? - The Globe and Mail
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Voya Investment Management LLC - MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN) - Insider Monkey
Portfolio Update: Can Regeneron Pharmaceuticals Inc reach all time highs this yearPortfolio Performance Report & Risk Managed Investment Signals - خودرو بانک
First Hawaiian Bank Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Geneos Wealth Management Inc. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - Defense World
Key metrics from Regeneron Pharmaceuticals Inc.’s quarterly dataMarket Trend Summary & Consistent Income Trade Ideas - newser.com
Intech Investment Management LLC Has $5.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Advisors Capital Management LLC Sells 801 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strs Ohio Takes $21.81 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
UniSuper Management Pty Ltd Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teza Capital Management LLC Sells 898 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Income Plays: What are the future prospects of Regeneron Pharmaceuticals Inc2025 Top Gainers & Precise Buy Zone Identification - خودرو بانک
Regeneron Pharmaceuticals, Inc. $REGN Holdings Boosted by Woodline Partners LP - MarketBeat
Belpointe Asset Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ascent Group LLC Purchases 937 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rush of Targeted Myasthenia Gravis Therapies Hit Once Sparse Market - BioSpace
Plato Investment Management Ltd Buys 1,116 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Custom strategy builders for tracking Regeneron Pharmaceuticals Inc.July 2025 Volume & Capital Efficient Trading Techniques - newser.com
Does Regeneron Offer Value After Recent Share Price Drop in 2025? - Yahoo Finance
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):